Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Applied Genetic Technologies Corp (AGTC), Oasis Petroleum Inc. (OAS) & More: A Look at Five Stocks Falling on Tuesday

Page 1 of 2

WTI futures are trading below $45 per barrel today after the IEA made some gloomy comments on demand growth. Perhaps taking its cue from oil, the broader market is also in the red as all three major indexes are off by more than 1.2% in afternoon trading.

Among the stocks that are underperforming the broader markets are Applied Genetic Technologies Corp (NASDAQ:AGTC), Momo Inc (ADR) (NASDAQ:MOMO), Oasis Petroleum Inc. (NYSE:OAS), Petroleo Brasileiro SA Petrobras (ADR) (NYSE:PBR), and Seadrill Ltd (NYSE:SDRL). In this article, we will take a closer look at the reasons behind the declines of these stocks and assess the smart money sentiment towards them.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

oil, rig, well, gas, oilman, job, russia, fuel, sunrise, power, business, controls, yellow, pump, jack, repairman, male, helmet, orange, drilling, sun, engineer, black, worker,

maradon 333/

Applied Genetic Technologies Corp (NASDAQ:AGTC) shares are off by over 32% after the company disclosed slower-than-planned enrollment in its XLRS Phase 1/2 Trial, which Applied Genetic is conducting in collaboration with Biogen Inc (NASDAQ:BIIB). So far in August, the company has eight out of the target number of up to 27 patients enrolled. The delays are due to patients not meeting eligibility criteria and due to the company making a protocol amendment to include the use of prophylactic corticosteroids that required further institutional review board approvals.

“The company has not observed any significant improvements in secondary endpoints in the six patients treated at the lowest dose level group. The company does not expect to report further data on the XLRS study this year, but intends to provide quarterly updates on its patient enrollment,” the company said

The secondary endpoints are measured in part to see if there are any early indications of potential efficacy (they are not as important as the primary endpoints, however). In addition, Applied Genetic’s ACHMB3 Phase 1/2 Trial is also experiencing slower-than-expected enrollment due to vendor errors. A total of 12 funds from our database were long Applied Genetic Technologies Corp (NASDAQ:AGTC) at the end of the second quarter, down by two funds from the previous quarter.

Follow Applied Genetic Technologies Corp (NASDAQ:AGTC)
Trade (NASDAQ:AGTC) Now!

Momo Inc (ADR) (NASDAQ:MOMO) shares have lost 6% so far today due to some profit taking. The stock has done very well year-to-date, having gained 50% before today. Given today’s news from the IEA that Chinese crude demand is somewhat soft, some traders are no doubt connecting the dots and anticipating a slower Chinese economic recovery. If that happens, Momo’s growth might not be as strong in dollar terms. According to our data, the number of elite funds with holdings in Momo Inc (ADR) (NASDAQ:MOMO) fell by 1 quarter-over-quarter to 9 at the end of June.

On the next page, we examine what is going on with Oasis Petroleum, Petroleo Brasileiro SA Petrobras, and Seadrill Ltd.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!